Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BPhytohealth Corp. 〉PHN014 (Acute ischemia stroke)

PHN014 (Acute ischemia stroke)

PHN014 (Acute ischemia stroke)

PG2 Injection new indication for treating Acute Ischemia Stroke. The multicenter clinical trial conducted at National Taiwan University Hospital, China Medical University Hospital and other 15 medical centers.

Request for Collaboration
Overview
Advantages of the product
  • PHN014 is extracted, isolated and refined with high purity from the Astragalus membranaceus (黃耆) , which has been described in the classical texts as a qi-supplementing medicine.
  • Long-term human experience show no drug- related toxicity
  • PHN014 meet the current trend of new drug development ,with two-way immune regulation
  • It's very safe and without the risk for inducing the intracranial hemorrhage
  • There is the potential for treating the Ischemic Stroke、accelerating the recovery from sequela and improving stroke prognosis.
Application
Potential use for treat Ischemic Stroke.
People who like this also like
  • Rapid Test (FMD NSP Ab test)Rapid Test (FMD NSP Ab test)
  • cGMP Complied Pilot FacilitycGMP Complied Pilot Facility
  • PHN031 (Osteoporosis prevention)PHN031 (Osteoporosis prevention)
  • CX-5461: RNA Polymerase I (Pol I) Inhibitor ProgramCX-5461: RNA Polymerase I (Pol I) Inhibitor Program
  • PHN033 (Diabetic Nephropathy treatment)PHN033 (Diabetic Nephropathy treatment)
  • Platform_BioSeizer™Platform_BioSeizer™
  • TLC590TLC590
  • TLC177TLC177
  • State-of-the-art FacilityState-of-the-art Facility
  • AmCAD CAAmCAD CA